What are the immunophenotypes of unclassifiable myelodysplastic syndromes (MDS-U)?

Answer

No specific immunophenotype of unclassifiable myelodysplastic syndromes (MDS-U) exists. However, in cases with a hemodilute aspirate but with 1% peripheral blood blasts, CD34 staining of the bone marrow trephine biopsy may help disclose increased and/or clustered blasts.^[11]If blasts appear to comprise at least 5% of the bone marrow biopsy cells by this method, a diagnosis of represent myelodysplastic syndrome (MDS) with excess blasts may be suggested rather than MDS-U.

Did this answer your question?

Yes No

Additional feedback? (Optional)

Thank you for your feedback!

Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30. 114 (5):937-51. [Medline].
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19. 127 (20):2391-405. [Medline].
Orazi A, Brunning RD, Baumann I, Hasserjian RP. Myelodysplastic syndrome, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 103.
Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Int Med. 2017 Sep. 5(3):139-43. [Medline]. [Full Text].
Hasserjian RP, Gupta P, Donohue K, et al. Application of the 2008 WHO Classification criteria for myelodysplastic syndromes without excess blasts: observations from Cancer and Leukemia Group B Study 10105 [abstract]. Mod Pathol. 2009. 22 (suppl 1):266A.
Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndrome, unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC Press; 2001. 72.
Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007 Apr. 21(4):668-77. [Medline].
Steensma DP, Dewald GW, Hodnefield JM, Tefferi A, Hanson CA. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Leuk Res. 2003 Mar. 27(3):235-42. [Medline].
Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 89, 93.
Shallis RM, Zeidan AM. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?. Best Pract Res Clin Haematol. 2020 Jun. 33 (2):101132. [Medline].
Soligo D, Delia D, Oriani A, et al. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody. Leukemia. 1991 Dec. 5(12):1026-30. [Medline].
Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Aug 15. 106(4):1207-9. [Medline]. [Full Text].
Wang SA, Hasserjian RP, Loew JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006 Sep. 20(9):1641-4. [Medline].
Gupta V, Brooker C, Tooze JA, et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol. 2006 Jul. 134(1):95-9. [Medline].
Soupir CP, Vergilio JA, Kelly E, Dal Cin P, Kuter D, Hasserjian RP. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol. 2009 Mar. 144(5):800-2. [Medline].
Keung YK, Pettenati MJ, Cruz JM, Powell BL, Woodruff RD, Buss DH. Bone marrow cytogenetic abnormalities of aplastic anemia. Am J Hematol. 2001 Mar. 66(3):167-71. [Medline].
Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002 May 1. 99(9):3129-35. [Medline].
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008 May 20. 26(15):2505-11. [Medline].
Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15. 110(8):2991-5. [Medline].
Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24. 123(17):2645-51. [Medline].
Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007 Nov. 31(11):1461-8. [Medline].
Knipp S, Strupp C, Gattermann N, et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res. 2008 Jan. 32(1):33-7. [Medline].
Baidoun F, Chen D, Patnaik M, et al. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leuk Lymphoma. 2019 Oct. 60 (10):2483-7. [Medline].

Media Gallery

Pathology of unclassifiable myelodysplastic syndromes (MDS-U). Bone marrow biopsy section from a patient with myelodysplastic syndrome, unclassifiable (MDS-U) (pancytopenia and -7 cytogenetic abnormality). The biopsy is hypocellular with hemosiderin deposition secondary to multiple transfusions. Megakaryocytes are not dysplastic.
Pathology of unclassifiable myelodysplastic syndromes (MDS-U). Bone marrow aspirate smear from a patient with myelodysplastic syndrome, unclassifiable (MDS-U) (pancytopenia and -7 cytogenetic abnormality). Occasional late mitotic figures in erythroid elements are present, but no significant erythroid or myeloid dysplasia exists.
Pathology of unclassifiable myelodysplastic syndromes (MDS-U). Cytogenetic analysis from a patient with myelodysplastic syndrome, unclassifiable (MDS-U), showing an abnormal 45, XX, -7 karyotype in 15 of 20 metaphases. In a patient with unexplained cytopenia, this finding confirms a diagnosis of MDS-U even in the absence of significant dysplasia in any lineage.

of 3

What are the immunophenotypes of unclassifiable myelodysplastic syndromes (MDS-U)?

Answer

Related Questions:

References

Tables

Contributor Information and Disclosures